Scafoglio, Claudio R <br/><br/>
Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma.  [electronic resource] 

 -  Science translational medicine  11 2018 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1946-6242 
<br/><br/><label>Standard No.: </label>10.1126/scitranslmed.aat5933  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma of Lung--diagnosis<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Biological Transport--drug effects<br/>Cell Differentiation<br/>Cell Proliferation--drug effects<br/>Female<br/>Glucose--metabolism<br/>Glucose Transporter Type 1--metabolism<br/>Humans<br/>Male<br/>Mice, SCID<br/>Mice, Transgenic<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Neoplasm Staging<br/>Positron-Emission Tomography<br/>Precancerous Conditions--metabolism<br/>Sodium-Glucose Transporter 2--metabolism<br/>Sodium-Glucose Transporter 2 Inhibitors--pharmacology<br/>Survival Analysis<br/>Xenograft Model Antitumor Assays